Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

In this issue

In this issue Purification of MLV‐ derived retroviral vectors for clinical gene therapy The rising demand for highly pure retroviral vectors for application in clinical trials emphasizes the need for development of efficient high‐throughput production and purification methods. To achieve high yields, the challenges relating to inherent instability of retroviral vectors and low titers produced by packaging cell lines need to be overcome. In this study, Rodrigues et al. devised a scaleable process for purification of murine leukaemia virus (MLV)‐derived vector supernatants based on membrane separation and anion‐exchange chromatography steps. This system resulted in a feasible and scaleable purification strategy for MLV‐derived vectors, allowing the removal of inhibitory contaminants, thus yielding pure vector stocks with increased transduction efficiencies. Targeted carboxylesterase overexpression increases tumour sensitivity to CPT‐11 Inducing expression of carboxylesterase (CE) enzymes, which convert the pro‐drug irinotecan (CPT‐11) into its cytotoxic metabolite, is a promising strategy for cancer gene therapy. Moreover, placing a CE transgene under the control of hypoxia‐responsive elements (HREs) should restrict its expression to tissues, like solid tumours, expressing the hypoxia‐inducible factor‐1 (HIF‐1). Here, Matzow et al. constructed a recombinant adenoviral vector, AdHRE‐rCE, where rabbit liver CE (rCE) cDNA is under the control of a HRE, derived from http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Gene Medicine Wiley

In this issue

Journal of Gene Medicine , Volume 9 (4) – Apr 1, 2007
Download PDF
2 pages

Loading next page...
 
/lp/wiley/in-this-issue-yZ6AzNsOfm

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wiley
Copyright
Copyright © 2007 John Wiley & Sons, Ltd.
ISSN
1099-498X
eISSN
1521-2254
DOI
10.1002/jgm.1042
Publisher site
See Article on Publisher Site

Abstract

Purification of MLV‐ derived retroviral vectors for clinical gene therapy The rising demand for highly pure retroviral vectors for application in clinical trials emphasizes the need for development of efficient high‐throughput production and purification methods. To achieve high yields, the challenges relating to inherent instability of retroviral vectors and low titers produced by packaging cell lines need to be overcome. In this study, Rodrigues et al. devised a scaleable process for purification of murine leukaemia virus (MLV)‐derived vector supernatants based on membrane separation and anion‐exchange chromatography steps. This system resulted in a feasible and scaleable purification strategy for MLV‐derived vectors, allowing the removal of inhibitory contaminants, thus yielding pure vector stocks with increased transduction efficiencies. Targeted carboxylesterase overexpression increases tumour sensitivity to CPT‐11 Inducing expression of carboxylesterase (CE) enzymes, which convert the pro‐drug irinotecan (CPT‐11) into its cytotoxic metabolite, is a promising strategy for cancer gene therapy. Moreover, placing a CE transgene under the control of hypoxia‐responsive elements (HREs) should restrict its expression to tissues, like solid tumours, expressing the hypoxia‐inducible factor‐1 (HIF‐1). Here, Matzow et al. constructed a recombinant adenoviral vector, AdHRE‐rCE, where rabbit liver CE (rCE) cDNA is under the control of a HRE, derived from

Journal

Journal of Gene Medicine – Wiley

Published: Apr 1, 2007

There are no references for this article.